Vaccine LU AF20513 is the their third Alzheimer's collaboration.
The company released two financial scenarios. The key is generic Copaxone.
Covidien is buying ingestible-camera company Given Imaging.
The drug is priced at $28,000 a month, before add-ons like ribivarin and (possibly) interferon.
The drug failed to hit its Phase III targets.
Novo's global diabetes study finds that only 29% of polled patients were asked what they thought about prescribed regimens.
Chronic disease patients seek online support and information, and show little love for branded websites.
Forest's cost-savings initiative is aimed at reducing operating expenses by $500 million, while Eisai said it's cutting 130 positions in the US and Europe.
Spectrum DNA says its genetic services are at the ready, even if 23andMe's are not.
The leukemia drug is staying on the market, but for a more restricted patient population.
The drugmaker says interim trial data meets FDA review requirements and is hoping for June 2014 approval.
Actavis shrinks its staff by 30%, and Bayer reduces its California footprint.
The agency's bad-ad warning letter calls the new violations "particularly troubling."
The patient population is small, at around 3,000, but the expected price tag is $330,000 a year.
Early clinical trial results indicate 81% of advanced melanoma patients survived for one year.
The catch is the difference between sales and revenues. Generics will continue to be a force, and small-audience drugs will become increasingly important.
Known as Breo Ellipta in the US, GlaxoSmithKline's Relvar Ellipta was approved by the EMA for asthma and COPD. The overall market is expected to continue to grow, but an NIH study indicates more patient conversations need to happen.
The US-only recall amounts to less than 1% of the company's inventory.
The current number is reported to hover around $4 billion.
The company says it will cut staff and costs, focus on big accounts and try to keep sales reps from leaving.
An investigational cardiovascular heart drug failed to reduce the risk of heart attack or stroke, a miss which some on Wall Street say raises questions about the drugmaker's ability to deliver in late-stage trials.
The company announced the layoffs Friday.
The FDA's Bad Ad group says the drugmaker misbranded its cholesterol drug during interviews on CNBC.
The company's pursuit of a tighter research focus follows a path very much like that of its peers.
A poll by consulting firm QPharma indicates doctors are in the dark about what needs to be reported and what will be revealed.
The drugmaker says 20 jobs, or 17% of its workforce, will be gone by the end of the year.
The "New Endo" will be one company on the outside, two on the inside.
The news is part of an ongoing reorg by the Swiss firm that is rumored to include selling off its animal health business.
A 15% increase in sales came on the back of HIV franchise meds Stribild and Complera/Eviplera.
Generic giant Teva refuted allegations that the CEO, Jeremy Levin, and the board of directors were at odds over the company's cost-saving maneuvers.
The company's hep. C drug Incivek peaked in 2011. Competition and pipeline drugs have forced the company to regroup.
The prostate cancer drug company is reportedly seeking a buyer to turn things around.
Based on its first three months on market, Tecfidera is one launch that's living up to its hype.
A court refuses to compel a government agency to schedule the firm's epilepsy drug, as the med's patent clock ticks.
The company says it is moving its Januvia sales pitch from defending market share to expanding it.
Vyvanse was one of six drugs with double-digit revenue increases, propelling sales of the specialty drugmaker Shire up 13% for the quarter.
A roundup of firms' quarterly performance culled from sources around the web.
Amid talk of cost containment, Lilly said it's also enjoying nice returns from some of its older diabetes drugs.
Word came of Breakthrough Designation for an HCV hopeful, a day after a hiccup in a heart drug trial.
BMS is showing signs of emerging from the cliff, but doubt lingers on Eliquis's slow launch in a post-Plavix marketplace.
Eli Lilly CEO John Lechleiter says he's not ready to cut his firm's $5.3-billion R&D budget just yet.
Lantus-like rivals can expect a wary reception from endocrinologists, even if these biosimilars reach market, researchers predict.
Eisai, the marketing half of the Arena-Eisai collaboration, plans to double the sales force by December.
The company beat consensus estimates, with particular sales strengths from its pharmaceuticals division.
The drug maker is beefing up its MedImmune offerings with a $440-million acquisition and a deal with ADC Therapeutics.
The drug maker is giving its inhaled insulin another go.
The Swiss biopharma is increasing capacity and investing $800 million in four locations.
The generics giant said it will lay off about 5,000 employees as it braces for the expiry of one of its specialty brands.
An analyst notes that early Phase III results in a psoriasis clinical trial could change the drug's efficacy profile. It could also fill out the financial potential of a standalone innovative unit, should Pfizer divide.
Three former workers are accused of giving proprietary data to a drug company abroad.
The group's offices will be in the DuBiotech research cluster.
The drug maker says it is accelerating development of new drugs and focusing on expanding indications of current ones.
A roundup of news related to hepatitis C.
The company it putting close to $4 billion towards developing pills that can replace insulin injections.
The CEO says Sanofi's patent-loss turnaround is coming.
A Credit Suisse analyst notes that the company will need to make a significant impact to meet even lowered expectations. A possible fix: more sales reps behind Belviq.
Echoing a strategy similar to that posed by Merck, the drug maker told investors that its strategy for hitting revenue targets includes efficiencies. It also depends on a regulatory-friendly pipeline.
The FDA approved the drug maker's depression drug Brintellix, one day after the Danish company announced a reorg that includes shifting 180 to 200 jobs.
The company will "fill the bag" of its sales reps, as part of a reorganization that also includes 8,500 job cuts and a more refined R&D focus.
Eli Lilly is the first Big Pharma to team up with the agency in its rare-disease pre-clinical development program.
Price, market potential and emotional pull make this subcategory of orphan diseases one to watch, an analyst writes. Hint: it's not oncology.
J&J grad Seth Fischer is replacing Zook as Vivus CEO, just two months after the former AstraZeneca exec's appointment.
Squeezed in the wet AMD space, Roche could get some eye-care breathing room if it can snag first-to-market status in the dry AMD category. Early results bode well.
Amgen's newest oncology asset could reach great heights, if the firm can capitalize on its existing commercial and R&D capabilities.
Analyst Seamus Fernandez writes that Merck needs to undergo a deep overhaul, continuing the summer narrative that has enveloped Pfizer and Novartis.
Early sales of NPS's Gattex have soared, while those of Protalix's Elelyso have been sluggish, underscoring the challenges of rare-disease launches.
Phase III results of Eli Lilly lung cancer drug necitumumab took analysts by surprise on two levels: by helping it avoid the dustbin and in succeeding where Erbitux had failed.
The company narrowed its second quarter loss, but said its national TV campaign is driving an uptick in consumer interest.
Novo redoubled its Victoza marketing efforts after a recent setback, and that's made things tougher for GLP-1 rivals Bristol-Myers Squibb and AstraZeneca.
This is the second addition this year and brings the company's contracted sales force to 260.
The drug maker, through its venture fund, took a controlling interest in the digital physician marketing firm.
Regeneron says it will seek a diabetes macular edema indication for Eylea this year, potentially encroaching on yet another Lucentis market.
HHS is looking into how J&J marketed opioid painkiller Nucynta, adding to the firm's list of investigations and those of the industry as a whole.
The positive way to frame the companies' quarterly results: "less bad," as generics continued to plague their balance sheets.
Companies are moving toward more access to clinical trial data. Despite their new stance, the internal battles haven't quite ended, some say.
The drug maker added biotechs Optimer and Trius to the fold, a bid to dominate in hard-to-treat infections.
While a strong launch of CF drug Kalydeco helped to hike the biotech's forecast, hep. C contender VTX-135 was hit with a partial clinical hold.
Pfizer said 2017 is the earliest the firm could split up. Meanwhile, sales dropped 7% year-on-year.
Quarterly sales fell 11% compared to the same period last year. The company plans on weathering a continued flow of patent losses with a narrower R&D focus.
The company said Monday it was putting up walls among its businesses and will begin financial reports for each of them starting in January. The key: each has its own emerging markets business unit.
Pharma's med-ed cut was its fifth in a row. But other income surged, filling the void as the funding picture for CME continued to even out.
Sales slid 9% during the second quarter, with generic Avapro and Plavix inflicting financial pain. The company says it is going to invest more to promote Eliquis among HCPs and plans on deploying a wider diabetes sales force.
Biogen Idec raised its full-year guidance on Tecfidera launch sales, as the MS market continues its growth trajectory.
The Indiana drug maker logged a 6% sales increase over the same period last year. Higher prices were responsible for the majority of the growth.
GlaxoSmithKline second-quarter sales rose 2% over the same period last year. CEO Andrew Witty says it is too early to tally the impact of China's corruption allegations.
Ranbaxy's ban from US soil has softened the blow for Novartis 2Q sales.
High points included an OTC rebound and strong performances from pharma.
FDA's afatinib approval enables the drug maker set up shop in a new therapy space.